Treatment with the highly selective IDH1 inhibitor ivosidenib led to a complete remission rate of 40%, with an overall survival of nearly 19 months in this group. Daniel Pollyea, MD, MS, shares results from this phase 1 study.
Recent Articles
AMA Announces New Approach to Physician Mental Health Care
The American Medical Association (AMA) has adopted a new policy designed to reduce the stigma of mental health problems among the medical community. The...
FDA Finds AbbVie Failed to Properly Investigate Patient Deaths
A recent inspection report from the U.S. Food and Drug Administration (FDA) revealed that AbbVie failed to properly investigate deaths that were reported in...
FDA Opens Communication Lines Between Drug Makers and Insurers
The U.S. Food and Drug Administration (FDA) has issued final guidance documents outlining the types of information that drug companies may share with insurers,...
Justice Department Will No Longer Defend ACA in Court
The U.S. Department of Justice has announced that it will no longer defend the Affordable Care Act (ACA) in court, a decision that could...
Rising Medicaid Costs Lead States to Adopt Accountable Care Organizations
As the burden of Medicaid expenditures on state budgets continues to grow, states are looking to new payment models to help reduce health-care costs...
Current Issue
June 2018, Volume 4, Issue 7
This issue features a look at gaining oral parity for cancer medications, the unavoidable "bubbles" in which people live and work, and more.
